Biofrontera (BFRI) Cash from Operations Growth (3y) (2023 - 2025)
Biofrontera (BFRI) Cash from Operations Growth (3y) (2023 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.69 Bn | 87.82 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.84 Bn | 32.10 Bn | 1.97 Bn | 34.90% |
| 3 | Zoetis | 32.67 Bn | 30.73 Bn | 1.62 Bn | -9.94% |
| 4 | Takeda Pharmaceutical | 27.69 Bn | 23.63 Bn | 4.39 Bn | -10.80% |
| 5 | United Therapeutics | 23.12 Bn | 20.97 Bn | 648.10 Mn | 7.32% |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.24 Bn | 18.44 Bn | 1.16 Bn | -26.33% |
| 8 | Neurocrine Biosciences | 17.83 Bn | 16.51 Bn | 800.70 Mn | 46.81% |
| 9 | Elanco Animal Health | 12.64 Bn | 12.22 Bn | 785.00 Mn | 27.85% |
| 10 | Biofrontera | 10.88 Mn | 4.47 Mn | 14.09 Mn | 33.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 33.74% |
| Sep 30, 2025 | 13.82% |
| Jun 30, 2025 | -208.23% |
| Mar 31, 2025 | -25.16% |
| Dec 31, 2024 | 63.75% |
| Sep 30, 2024 | -1.73% |
| Jun 30, 2024 | -62.39% |
| Mar 31, 2024 | 0.99% |
| Dec 31, 2023 | -133.77% |